AVIR
Atea Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +13.3% ·
share flow +1.2% ·
net new positions +11.8%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 62 | -4 | 39.30M | $182.78M | +3 | −7 |
| Q1 2026 | 68 | +5 | 39.11M | $209.92M | +8 | −3 |
| Q4 2025 | 63 | +1 | 37.55M | $134.03M | +1 | n/a |
| Q3 2025 | 17 | +2 | 27.75M | $80.49M | +2 | n/a |
| Q2 2025 | 12 | 0 | 25.41M | $91.49M | +1 | −1 |
| Q1 2025 | 9 | -1 | 6.11M | $18.26M | n/a | −1 |
| Q4 2024 | 10 | +1 | 6.07M | $20.35M | +2 | −1 |
| Q3 2024 | 8 | 0 | 4.57M | $15.30M | +1 | −1 |
| Q2 2024 | 8 | n/a | 4.70M | $15.57M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 8.46M | -2.4% | $24.53M | 0.0% | ▼ Trim | 2 | SEC ↗ ×10 |
| 2 | Fidelity (FMR) ✦ | 5.82M | +1.8% | $16.89M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 3 | The Vanguard Group ✦ (passive) | 4.71M | -3.6% | $13.66M | 0.0% | ▼ Trim | 2 | SEC ↗ ×3 |
| 4 | Geode Capital Management ✦ (passive) | 1.90M | -1.3% | $5.51M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 5 | State Street Global Advisors ✦ (passive) | 1.78M | +0.4% | $5.17M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | JPMorgan Chase ✦ | 1.23M | n/a | $3.58M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 7 | Renaissance Technologies ✦ | 1.23M | -0.5% | $3.56M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 8 | Millennium Management ✦ | 487.22K | +179.2% | $1.41M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 9 | Two Sigma Investments ✦ | 471.29K | +28.6% | $1.37M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 10 | Morgan Stanley ✦ | 450.56K | n/a | $1.31M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 11 | D. E. Shaw & Co. ✦ | 364.77K | +86.2% | $1.06M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 12 | Goldman Sachs Group ✦ | 340.14K | n/a | $986,406 | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 13 | Wellington Management ✦ | 262.77K | -26.9% | $762,048 | 0.0% | ▼ Trim | 6 | SEC ↗ ×3 |
| 14 | T. Rowe Price ✦ | 97.53K | +22.1% | $283,000 | 0.0% | ▲ Add | 6 | SEC ↗ |
| 15 | Marshall Wace ✦ | 87.06K | +250.1% | $252,474 | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 16 | Citadel Advisors ✦ | 41.73K | New | $121,014 | 0.0% | New | 1 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 13.41K | New | $38,889 | 0.0% | New | 1 | SEC ↗ ×3 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Citadel Advisors | $121,014 | 0.0% |
| AQR Capital Management | $38,889 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 126 holders, 59.16M shares, $308.71M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.